

# Arthritis and Rheumatism

*Official Journal of the ARA Section of the Arthritis Foundation*

## **CONTENTS**

### No. 1 (February)

INFLUENCE OF HUMAN RHEUMATOID FACTOR ON NUMBERS OF ANTIBODY-PRODUCING CELLS .....	<i>John C. Brown and Wallace V. Epstein</i>	1
FAMILY STUDIES IN SYSTEMIC LUPUS ERYTHEMATOSUS. I. PRENATAL FACTORS .....	<i>Arthur Oleinick</i>	10
LIVER XANTHINE OXIDASE IN GOUTY PATIENTS .....	<i>Aldo Carcassi,</i> <i>Roberto Marcolongo, Jr., Enrico Marinello, Giuseppe Riario-Sforza,</i> <i>and Carlo Boggiano</i>	17
COLLAGEN OF HUMAN ARTICULAR AND COSTAL CARTILAGE .....	<i>Edward J. Miller, Jan K. van der Korst, and Leon Sokoloff</i>	21
ELIMINATION OF Na <sup>131</sup> I FROM THE HEAD AND THE NECK OF THE FEMUR IN UNAFFECTED AND OSTEOARTHRITIC HIP JOINTS .....	<i>Jerker Hernborg</i>	30
BENEFICIAL EFFECT OF IMMOBILIZATION OF JOINTS IN RHEUMATOID AND RELATED ARTHRIDES: A SPLINT STUDY USING SEQUENTIAL ANALYSIS .....	<i>Sarah J. Gault and Joan M. Spyker</i>	34
CURRENT COMMENT: ON THE MECHANISMS OF TRANSPORT AND BIOLOGICAL SIGNIFICANCE OF ANTIBODIES IN EXTERNAL SECRETIONS .....	<i>Thomas B. Tomasi, Jr.</i>	45
ARTHRITIS ROUNDS: RESORPTION OF THE TERMINAL PHALANGES IN SCLERODERMA .....	<i>Lawrence Scharer and Donald W. Smith</i>	51
DISCUSSION .....	<i>Gerald P. Rodnan and H. Edward Holling</i>	56
COMMUNICATIONS: IN VIVO LUPUS ERYTHEMATOSUS CELLS .....	<i>Herbert R. Dyer and Burton Zuckerman</i>	64
AMERICAN RHEUMATISM ASSOCIATION .....		65

### No. 2 (April)

COLD-REACTIVE RHEUMATOID FACTORS IN INFECTIOUS MONONUCLEOSIS AND OTHER DISEASES .....	<i>J. Donald Capra, Robert J. Winchester, and Henry G. Kunkel</i>	67
---	---	----

REACTIVITY OF RHEUMATOID FACTOR WITH AUTOLOGOUS IgG ANTIBODIES <i>Klaus K. Bandilla and Frederic C. McDuffie</i>	74
THE RELATIONSHIP OF RHEUMATOID FACTOR TO AGE OF ONSET IN JUVENILE RHEUMATOID ARTHRITIS <i>Virgil Hanson, Elizabeth Drexler, and Helen Kornreich</i>	82
A FOUR YEAR FOLLOW-UP OF SUSPECTED RHEUMATOID ARTHRITIS: THE TE- CUMSEH, MICHIGAN, COMMUNITY HEALTH STUDY <i>William M. Mikkelsen and Horace Dodge</i>	87
SYNOVIAL COLLAGENASE: ITS PRESENCE IN CULTURE FROM JOINT DISEASE OF DIVERSE ETIOLOGY <i>Edward D. Harris, Jr., George L. Cohen, and Stephen M. Krane</i>	92
ARTHRITIS INDUCED IN RABBITS BY LYSATES OF GRANULOCYTE LYSOSOMES <i>Gerald Weissmann, Isaias Spilberg, and Kathrin Krakauer</i>	103
SURVIVORSHIP IN SYSTEMIC LUPUS ERYTHEMATOSUS: RELATIONSHIP TO RACE AND PREGNANCY ..... <i>Morris Siegel, Nancy Gwon, Stanley L. Lee, Isaac Rivero, and William Wong</i>	117
THE ARTHRITIS OF SARCOIDOSIS <i>Isaias Spilberg, Louis E. Siltzbach, and Currier McEwen</i>	126
AORTIC INSUFFICIENCY IN SYSTEMIC LUPUS ERYTHEMATOSUS <i>Herbert J. Shulman and Charles L. Christian</i>	138
ARTHRITIS ROUNDS: GIANT CELL ARTERITIS WITH POLYMYALGIA RHEUMATICA, LOSS OF VISION, AND ABNORMAL SYMPTOMS OCCURRING DURING A FOUR YEAR COURSE ..... <i>Peter A. Simkin and L. A. Healey</i>	147
DISCUSSION ..... <i>Carl M. Pearson and Charles M. Plotz</i>	150
CURRENT COMMENT: AN ESSAY ON THE BIOLOGY OF OSTEOARTHRITIS <i>Alfred Jay Bollet</i>	152
AMERICAN RHEUMATISM ASSOCIATION .....	164
No. 3. (June)	
IMMUNOLOGIC AND CLINICAL OBSERVATIONS OF GRANULOCYTE-SPECIFIC ANTI- NUCLEAR ANTIBODIES ..... <i>Kathryn H. Svec</i>	165
SPECIFICITY AND REACTIVITY OF CYTOPLASMIC AND NUCLEOLAR ANTIBODY IN SLE SERA <i>Nobuo Watanabe, Herbert M. Fisher, and Wallace V. Epstein</i>	173
POLYMORPHONUCLEAR LEUKOCYTE MOTILITY IN VITRO. I. EFFECT OF pH, TEMPERATURE, ETHYL ALCOHOL, AND CAFFEINE, USING A MODIFIED BOYDEN CHAMBER TECHNIC ..... <i>Paulding Phelps and Diana Stanislaw</i>	181

POLYMORPHONUCLEAR LEUKOCYTE MOTILITY IN VITRO. II. STIMULATORY EFFECT OF MONOSODIUM URATE CRYSTALS AND URATE IN SOLUTION; PARTIAL INHIBITION BY COLCHICINE AND INDOMETHACIN .....	<i>Paulding Phelps</i>	189
POLYMORPHONUCLEAR LEUKOCYTE MOTILITY IN VITRO. III. POSSIBLE RELEASE OF A CHEMOTACTIC SUBSTANCE AFTER PHAGOCYTOSIS OF URATE CRYSTALS BY POLYMORPHONUCLEAR LEUKOCYTES .....	<i>Paulding Phelps</i>	197
THE STROMAL CELL REACTION OF PIGMENTED VILLONODULAR SYNOVITIS: AN ELECTRON MICROSCOPIC STUDY .....	<i>John C. Wyllie</i>	205
BONE MARROW AS SOURCE OF CELLS IN REACTIONS OF CELLULAR HYPERSENSITIVITY. III. ADJUVANT ARTHRITIS IN THE RAT <i>Deborah A. Putnam, David M. Lubaroff, and Byron H. Waksman</i>		215
EXTERNAL COUNTING AND SCINTIPHOTOGRAPHY IN RABBITS WITH ARTHRITIS <i>Stephen D. Sholkoff, Morton G. Glickman, Julius Schachter, and Malcolm Rowland</i>		220
BASAL URINARY PYROPHOSPHATE EXCRETION IN PSEUDOGOUT <i>Michael Pfleug, Daniel J. McCarty, and Frank Kawahara</i>		228
MURINE AMYLOID. II. TRANSFER OF AN AMYLOID-ACCELERATING SUBSTANCE <i>James T. Willerson, Joyce K. Gordon, Norman Talal, and Werner F. Barth</i>		232
THE COINCIDENCE OF KLINEFELTER'S SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS .....	<i>Carmen Ortiz-Neu and E. Carwile LeRoy</i>	241
RELATIONSHIP OF LETHAL MIDLINE GRANULOMA TO WEGENER'S GRANULOMATOSIS .....	<i>Leroy J. Byrd, Martin A. Shearn, and W. H. Tu</i>	247
CURRENT COMMENT: ANTITISSUE ANTIBODIES AND IMMUNOLOGICAL TOLERANCE TO SELF .....	<i>D. M. Weir and C. J. Elson</i>	254
ARTHRITIS ROUNDS: HYPERTROPHIC OSTEOARTHROPATHY WITH ARTHRITIS AND SYNOVIAL CALCIFICATION IN A PATIENT WITH ALCOHOLIC CIRRHOSIS <i>Elliott D. Kieff and Daniel J. McCarty, Jr.</i>		261
DISCUSSION .....	<i>David S. Howell and Edward A. Gall</i>	269
IN MEMORIAM: EDWARD F. HARTUNG, 1899-1969 .....		272
AMERICAN RHEUMATISM ASSOCIATION: ABSTRACTS OF PAPERS SUBMITTED TO THE ANNUAL MEETING, JUNE, 1969 .....		275
No. 4 (August)		
ARTHROGRYPOSIS MULTIPLEX CONGENITA AND SPONTANEOUS CARPAL FUSION <i>D. S. Newcombe, Jay L. Abbott, W. J. Munsie, and T. E. Keats</i>		345
AUTOANTIBODIES AND NEPHRITIS IN THE WHITE STRAIN (NZW) OF NEW ZEALAND MICE .....	<i>Bevera H. Hahn and Lawrence E. Shulman</i>	355

LEUKOCYTE-CONNECTIVE TISSUE CELL INTERACTION. I. STIMULATION OF HYALURONATE SYNTHESIS BY LIVE AND DEAD LEUKOCYTES <i>Michael Yaron and C. William Castor</i>	365
LEUKOCYTE-CONNECTIVE TISSUE CELL INTERACTION. II. THE SPECIFICITY, DURATION, AND MECHANISM OF INTERACTION EFFECTS <i>C. William Castor and Michael Yaron</i>	374
THE MICROVASCULATURE OF THE SYNOVIAL MEMBRANE OF THE MONKEY: ULTRASTRUCTURAL STUDIES ..... <i>H. Ralph Schumacher, Jr.</i>	387
OSTEOARTHRITIS OF THE METACARPOPHALANGEAL JOINT: HOOK-LIKE OSTEOPHYTES ..... <i>Robert L. Swezey, J. B. Peter, and Peter L. Evers</i>	405
JUVENILE RHEUMATOID ARTHRITIS IN A MOTHER AND HER IDENTICAL TWIN SONS ..... <i>M. A. Kapusta, J. D. Metrakos, L. Pinsky, J. L. Shugar, and A. P. Naimark</i>	411
RESECTION OF THE DISTAL URNA IN RHEUMATOID ARTHRITIS <i>Andrea Cracchiolo, III, and Leonard Marmor</i>	415
ANTERIOR OCCIPITOCERVICAL FUSION IN RHEUMATOID ARTHRITIS: REPORT OF A CASE ..... <i>J. Robin deAndrade and Ian Macnab</i>	423
CURRENT COMMENT: THE CHEMISTRY AND STRUCTURE OF BASEMENT MEMBRANES ..... <i>Nicholas A. Kefalides</i>	427
ARTHRITIS ROUNDS: AMYLOID ARTHROPATHY <i>Gerson C. Bernhard and George T. Hensley</i>	444
DISCUSSION ..... <i>Daniel J. McCarty, Merrill D. Benson, Alan S. Cohen, and Harry Bartfeld</i>	451
THE ADVERSE EFFECT OF INTRAVENOUS IRON-DEXTRAN IN RHEUMATOID ARTHRITIS ..... <i>P. S. Reddy and Marvin Lewis</i>	454
COMMUNICATION: NONCERULOPLASMIN COPPER IN RHEUMATOID ARTHRITIS <i>Irmin Sternlieb, John I. Sandson, Anatol G. Morell, Edith Korotkin, and I. Herbert Scheinberg</i>	458
DISCUSSION ..... <i>Arthur Lorber</i>	459
AMERICAN RHEUMATISM ASSOCIATION .....	461
No. 5 (October)	
THE INHIBITION OF ADJUVANT DISEASE IN RATS BY THE INTERFERON-INDUCING AGENT PYRAN COPOLYMER ..... <i>M. A. Kapusta and J. Mendelson</i>	463
COMPARATIVE BIOASSAY OF DRUGS IN ADJUVANT-INDUCED ARTHRITIS IN RATS: FLUFENAMIC ACID, MEFENAMIC ACID, AND PHENYLBUTAZONE <i>Claude V. Winder, Lois A. Lemke, and Marvin D. Stephens</i>	472

- RADIOIMMUNOASSAY OF RHEUMATOID FACTOR ..... *P. Franchimont and S. Suteanu* 483
- EXPERIMENTAL CORTICOSTEROID MYOPATHY ..... *Michael G. Sheahan and Paul J. Vignos, Jr.* 491
- MECHANISM OF COMPLEMENT BINDING BY THE RED CELL IN RHEUMATOID ARTHRITIS ..... *Bruce C. Gilliland and Elizabeth Turner* 498
- THE REMOVAL OF AGGREGATED AND NONAGGREGATED AUTOLOGOUS GAMMA GLOBULIN FROM RHEUMATOID JOINTS ..... *Anthony J. Sliwinski and Nathan J. Zvaifler* 504
- NEGATIVE RESULT: TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH GAMMA GLOBULIN: A DOUBLE-BLIND CONTROLLED STUDY ..... *Jerome H. Herman, Hugo E. Jasin, J. Donald Smiley, and Morris Ziff* 515
- ARTHRITIS ROUNDS: RECURRENT HEMARTHROSIS AFTER PROSTHETIC KNEE ARTHROPLASTY: IDENTIFICATION OF METAL PARTICLES IN THE SYNOVIAL FLUID ..... *Rodanthi C. Kitridou, H. Ralph Schumacher, Jr., John L. Sbarbaro, and Joseph L. Hollander* 520
- DISCUSSION ..... *Paul H. Curtiss, Jr., William T. Green, and Patrick G. Laing* 527
- CURRENT COMMENT: ONGOING ASSESSMENT OF THERAPY IN SEPTIC ARTHRITIS ..... *Frank R. Schmid and Richard H. Parker* 529
- BOOK REVIEWS: MEDITATIONS ON GOUT ..... *Reviewed by Gerald P. Rodnan* 535
- INTRODUCTION TO MEDICAL DECISION MAKING ..... *Reviewed by James A. Boyle* 535
- AIDS AND ADAPTATIONS: A COLLECTION OF DESIGNS COMPILED BY THE OCCUPATIONAL THERAPY DEPARTMENT, THE CANADIAN ARTHRITIS AND RHEUMATISM SOCIETY, BRITISH COLUMBIA DIVISION, VANCOUVER, B.C. ..... *Reviewed by John F. Ditunno, Jr.* 536
- EARLY SYNOVECTOMY IN RHEUMATOID ARTHRITIS ..... *Reviewed by Robert S. Pinals* 536
- COMMUNICATIONS: CYCLOPHOSPHAMIDE TREATMENT OF RHEUMATOID ARTHRITIS ..... *William M. Fosdick* 538
- IMPAIRED RENAL ACIDIFICATION IN SJÖGREN'S SYNDROME AND RELATED DISORDERS ..... *H. Benfer Kaltreider and Norman Talal* 538
- CYTOPLASMIC TUBULAR STRUCTURES IN KIDNEY BIOPSIES IN SYSTEMIC LUPUS ERYTHEMATOSUS ..... *Eric R. Hurd, Edwin Eigenbrodt, Morris Ziff, and Stanley W. Strunk* 541

EDITOR'S NOTE .....	543
SEROLOGICAL REACTIONS OF THE RHEUMATOID FACTORS <i>Marion Waller</i>	543
THE PRESENT STATUS OF ANTINUCLEAR ANTIBODY SEROLOGY <i>Eugene V. Barnett and Naomi Rothfield</i>	543
CHOICE OF TEST FOR MEASUREMENT OF ANTIGLOBULIN FACTORS .....	545 <i>Wallace V. Epstein</i>
AMERICAN RHEUMATISM ASSOCIATION .....	546

## No. 6 (December)

ALTERED REACTIVITY IN MIXED LYMPHOCYTE CULTURE OF LYMPHOCYTES FROM PATIENTS WITH RHEUMATOID ARTHRITIS <i>Gonzalo P. Astorga and Ralph C. Williams, Jr.</i>	547
RHEUMATOID ARTHRITIS, DYSPROTEINEMIC ARTHROPATHY, AND PARAPROTEINE- MIA .....	555 <i>Zbigniew A. Zawadzki and Thomas G. Benedek</i>
THE ASSOCIATION OF RHEUMATOID ARTHRITIS WITH PLASMA CELL AND LYMPHO- CYTIC NEOPLASMS .....	569 <i>Gerald J. Goldenberg, Frixos Paraskevas, and Lyonel G. Israels</i>
IDENTIFICATION OF COLLAGEN IN SYNOVIAL FLUID .....	580 <i>Rodanthi Kitridou, Daniel J. McCarty, Darwin J. Prockop, and Klaus Hummeler</i>
IMMUNOLOGICAL STUDIES OF AN EXPERIMENTAL CHRONIC ARTHRITIS RESEM- BLING RHEUMATOID ARTHRITIS .....	589 <i>Gonzalo P. Astorga</i>
HUMAN LYMPHOCYTE TRANSFORMATION INDUCED BY ANTI-GAMMA GLOBULIN FACTORS <i>Richard A. King, Ronald P. Messner, and Ralph C. Williams, Jr.</i>	597
PROCAINAMIDE-INDUCED SEROLOGIC CHANGES IN ASYMPTOMATIC PATIENTS <i>Javier Molina, Edmund L. Dubois, Michael Bilitch, Stephen L. Bland, and George J. Friou</i>	608
EXPERIMENTAL MURINE AMYLOID. III. AMYLOIDOSIS INDUCED WITH ENDO- TOXINS .....	615 <i>Werner F. Barth, James T. Willerson, Richard Aszofsky, John N. Sheagren, and Sheldon M. Wolff</i>
JOINT INFECTION BY ANAEROBIC BACTERIA: A CASE REPORT AND REVIEW OF THE LITERATURE .....	627 <i>Irwin Ziment, Alvin Davis, and Sydney M. Finegold</i>
CRST SYNDROME AND "NEUROPATHIC" ARTHROPATHY .....	636 <i>Irving Karten</i>
CURRENT COMMENT: SIGNIFICANCE OF PERSISTENT DIFFERENCES BETWEEN NORMAL AND RHEUMATOID SYNOVIAL MEMBRANE CELLS IN CULTURE <i>Carol Smith and David Hamerman</i>	639

## CONTENTS

## IX

COMMUNICATIONS: IDIOPATHIC JOINT APOPLEXY .....	<i>Alfred Miller</i> 646
SYNOVIAL HEMANGIOMA OF THE KNEE ..... <i>Jack Stevens,     Paul L. Katz, Francis L. Archer, and Daniel J. McCarty</i> 647	
BOOK REVIEWS: LA MAIN RHUMATOIDE/THE RHEUMATOID HAND	
<i>Reviewed by Jack Stevens</i> 650	
POPULATION STUDIES OF THE RHEUMATIC DISEASES	
<i>Reviewed by Alfonse T. Masi</i> 650	
NONBOARD REVIEWERS, 1968-1969 .....	652
AMERICAN RHEUMATISM ASSOCIATION: ABSTRACTS OF PAPERS SUBMITTED TO THE INTERIM MEETING, DECEMBER, 1969 .....	653

## INDEX OF AUTHORS

- Abbott, J. L., 345  
Archer, F. L., 647  
Asofsky, R., 615  
Astorga, G. P., 547, 589  
  
Bandilla, K. K., 74  
Barnett, E. V., 543  
Bartfeld, H., 451  
Barth, W. F., 232, 615  
Benedek, T. G., 555  
Benson, M. D., 451  
Bernhard, G. C., 444  
Bilitch, M., 608  
Bland, S. L., 608  
Boggiano, C., 17  
Bollet, A. J., 152  
Boyle, J. A., 535  
Brown, J. C., 1  
Byrd, L. J., 247  
  
Capra, J. D., 67  
Castor, C. W., 365, 374  
Christian, C. L., 138  
Cohen, A. S., 451  
Cohen, G. L., 92  
Cracchiolo, III, A., 415  
Curtiss, Jr., P. H., 527  
  
Davis, A., 627  
deAndrade, J. R., 423  
Ditunno, Jr., J. F., 536  
Dodge, H., 87  
Drexler, E., 82  
Dubois, E. L., 608  
Dyer, H. R., 64  
  
Eigenbrodt, E., 541  
Elson, C. J., 254  
Epstein, W. V., 1, 173, 545  
Evers, P. L., 405  
  
Finegold, S. M., 627  
Fisher, H. M., 173  
Fosdick, W. M., 538  
Franchimont, P., 483  
Friou, G. J., 608  
  
Gall, E. A., 269  
Gault, S. J., 34  
Gilliland, B. C., 498  
Glickman, M. G., 220  
Goldenberg, G. J., 569  
Gordon, J. K., 232  
Greene, W. T., 527  
Gwon, N., 117  
  
Hahn, B. H., 355  
Hamerman, D., 639  
Hanson, V., 82  
Harris, Jr., E. D., 92  
Healey, L. A., 147  
Hensley, G. T., 444  
Herman, J. H., 515  
Hernborg, J., 30  
Hollander, J. L., 520  
Holling, H. E., 56  
Howell, D. S., 269  
Hummeler, K., 580  
Hurd, E. R., 541  
  
Israels, L. G., 569  
  
Jasin, H. E., 515  
  
Kaltreider, H. B., 538  
Kapusta, M. A., 411, 463  
Karten, I., 636  
Katz, P. L., 647  
Kawahara, F., 228  
Keats, T. E., 345  
Kefalides, N. A., 427  
Kieff, E. D., 261  
King, R. A., 597  
Kitridou, R. C., 520, 580  
Kornreich, H., 82  
Korotkin, E., 458  
Krakauer, K., 103  
Krane, S. M., 92  
Kunkel, H. G., 67  
  
Laing, P. G., 527  
Lee, S. L., 117  
Lembke, L. A., 472  
LeRoy, E. C., 241  
Lewis, M., 454  
Lorber, A., 459  
Lubaroff, D. M., 215  
  
Macnab, I., 423  
Marcolongo, Jr., R., 17  
Marinello, E., 17  
Marmor, L., 415  
Masi, A. T., 650  
McCarthy, D. J., 228, 261,  
    451, 580, 647  
McDuffie, F. C., 74  
McEwen, C., 126  
Mendelson, J., 463  
Messner, R. P., 597  
Metakos, J. D., 411  
  
Mikkelsen, W. M., 87  
Miller, A., 646  
Miller, E. J., 21  
Molina, J., 608  
Morell, A. G., 458  
Munsie, W. J., 345  
  
Naimark, A. P., 411  
Newcombe, D. S., 345  
  
Oleinick, A., 10  
Ortiz-Neu, C.  
  
Paraskevas, F., 569  
Parker, R. H., 529  
Pearson, C. M., 150  
Peter, J. B., 405  
Pflug, M., 228  
Phelps, P., 181, 189, 197  
Pinals, R. S., 536  
Pinsky, L., 411  
Plotz, C. M., 150  
Prockop, D. J., 580  
Putnam, D. A., 215  
  
Reddy, P. S., 454  
Riario-Sforza, G., 17  
Rivero, I., 117  
Rodnan, G. P., 56  
Rothfield, N., 543  
Rowland, M., 220  
  
Sandson, J. I., 458  
Sbarbaro, J. L., 520  
Schachter, J., 220  
Scharer, L., 51  
Scheinberg, I. H., 458  
Schmid, F. R., 529  
Schumacher, Jr., H. R., 387,  
    520  
Sheagren, J. N., 615  
Sheahan, M. G., 491  
Shearn, M. A., 247  
Sholkoff, S. D., 220  
Shugar, J. L., 411  
Shulman, H. J., 138  
Shulman, L. E., 355  
Siegel, M., 117  
Siltzbach, L. E., 126  
Simkin, P. A., 147  
Slivinski, A. J., 504  
Smiley, J. D., 515  
Smith, C., 639  
Smith, D. W., 51

- Sokoloff, L., 21  
Spilberg, I., 103, 126  
Spyker, J. M., 34  
Stanislaw, D., 181  
Stephens, M. D., 472  
Sternlieb, I., 458  
Stevens, J., 647, 650  
Strunk, S. W., 541  
Suteanu, S., 483  
Svec, K. H., 165  
Swetsey, R. L., 405  
  
Talal, N., 232, 538  
Tomasi, Jr., T. B., 45
- Tu, W. H., 247  
Turner, E., 498  
  
van der Korst, J. K., 21  
Vignos, Jr., P. J., 491
- Waksman, B. H., 215  
Waller, M., 543  
Watanabe, N., 173  
Weir, D. M., 254  
Weissman, G., 103  
Willerson, J. T., 232, 615  
Williams, Jr., R. C., 547, 597
- Winchester, R. J., 87  
Winder, C. V., 472  
Wolff, S. M., 615  
Wong, W., 117  
Wyllie, J. C., 205
- Yaron, M., 365, 374
- Zawadzki, Z. A., 555  
Ziff, M., 515, 541  
Ziment, I., 627  
Zvaipler, N. J., 504  
Zweiman, B., 64

## INDEX OF SUBJECTS

Page numbers in *italics* indicate abstracts

- Abdominal symptoms in giant cell arteritis, 147-151  
Acetylsalicylic acid. *See Salicylates*  
Acidification, renal, in Sjögren's syndrome, 538-541  
Adjuvant arthritis. *See Experimental arthritis*  
Aged, rheumatoid arthritis in, 291  
Agglutination inhibition antibodies, rubella, in RA, 671  
Agglutination test, sheep cell, amboceptor affecting, 660  
Agglutinators  
    Fab papain, affecting immune hemolysis, 340  
    pepsin-site, affecting phagocytosis, 682  
Albumin, amino acid composition of, in Ehlers-Danlos syndrome, 289-290  
Alcohol, ethyl, affecting PMN motility, 181-187  
Alcoholic cirrhosis, with hypertrophic osteoarthropathy, 261-271  
Alkaptonuria  
    enzyme defect in, 160  
    homogentisic acid turnover in, 678-679  
    laboratory artifacts in, 673  
Allergic encephalomyelitis. *See Encephalomyelitis*  
Allopurinol, affecting cultured fibroblasts, 306-307  
Alpha-1-antitrypsin levels in RA, 337  
Aluminum metabolism in RA, 684  
Amboceptor, affecting sheep cell agglutination test, 660  
American Rheumatism Association  
    abstracts from annual meeting, 275-344  
    abstracts from interim meeting, 653-705  
Allied Health Professions Section meeting, 462  
Hartung, Edward F., 272-274  
International Symposium on Tissue and Blood Antigens, 462  
International Workshop of Artificial Finger Joints, 546  
new officers elected, 462  
Rheumatoid Factors Conference, 164  
Robecchi Foundation, 65  
Symposium on Crippling Foot, 65  
Tucson meeting, 546  
Ward elected president, 461  
Amino acids  
    in albumin in Ehlers-Danlos syndrome, 289-290  
    in amyloid fibril proteins, 333  
    in cartilage, 21-28  
    in collagen from basement membrane, 434  
Ampicillin transport, into synovial fluid, 686  
Amyloid  
    accelerating substance, transfer of, 232-240  
    and arthropathy, 444-453  
    cerebral, 343  
    fibril proteins, chemical differences in, 333  
Amyloidosis  
    and carpal tunnel syndrome, 560  
    from endotoxins, 615-624  
    and rheumatoid arthritis, 562  
Anaerobes, joint infection from, 627-632  
Ankylosing spondylitis. *See Spondylitis*  
Antibiotics  
    in bedsonia arthritis, 297  
    transport into joints, 529-531, 686  
Antibodies  
    antinuclear. *See Antinuclear antibodies*  
    antitissue, and immunological tolerance to self, 254-258  
    autoantibodies  
        in burned patients, 691  
        in NZB mice, 355-363  
    cytoplasmic, in SLE sera, 173-179  
    to DNA. *See DNA*  
    in external secretions, 45-49  
    hapten-specific anamnestic responses of, 686-687  
    immune response affecting collagen turnover of tendon grafts, 676  
    immunoglobulin D, 672  
    nucleolar  
        sex affecting, 326  
        in SLE sera, 173-179  
    to nucleoproteins after isoniazide, 275  
    responses to protein antigens in strains of mice, 300-301  
    rheumatoid factor affecting cells producing, 1-8 to ribosomes  
        in IgG subgroups, 695  
        in SLE, 310  
    to RNA. *See RNA*  
    rubella hemagglutination inhibition, in RA, 671  
    viruses affecting formation of, 670  
Anti-i as new cold antibody, 72  
Antiinflammatory agents, regional perfusion of, 662  
Antinuclear antibodies  
    in chronic articular inflammation, 344  
    correspondence on, 543-545  
    detection of, 656  
    granulocyte-specific, 165-171  
    immunoglobulin G, subclasses of, 295, 671, 695  
    immunologic correlates of, in juvenile RA, 323-324  
    in juvenile RA, 85

- Antinuclear antibodies (continued)
- in lupus nephritis, 280
  - in NZB mice, 355-363
  - after oral contraceptives, 306, 313-314
  - after procainamide, 608-613
  - in sarcoidosis, 130
  - in scleroderma in childhood, 301-302
  - sex affecting, 326
- Antituberculosis serum, rabbit, suppressing experimental diseases, 319
- Aortic insufficiency in lupus erythematosus, 138-145
- Apoplexy, joint, idiopathic, 287, 646
- Arteritis
- giant cell, and polymyalgia rheumatica, 147-151
  - and rheumatoid arthritis, 305
  - involving large vessels, 319
  - from steroids, 327
  - systemic, scintigraphy in, 294
- Arthritis
- acute, from rubella vaccination, 701
  - adjuvant. *See Experimental arthritis*
  - bacterial
    - assessment of therapy in, 529-532
    - synovial collagenase in, 94  - bedsonia
    - antibiotics in, 297
    - scintiphotography in, 220-227  - experiences with mobile clinics, 689-690
  - in experimental scurvy, 670
  - hip prosthesis in, total, 313, 318
  - from hydralazine, histidine levels in, 295-296
  - of hypertrophic osteoarthropathy with cirrhosis, 261-271
  - osteoarthritis. *See Osteoarthritis*
  - periartthritis from 6-sulfamilamidoindazole, 702-703
  - peripheral, and ankylosing spondylitis, 680-681
  - polyarthritides in obese patients, after jejunocolonic bypass, 696
  - purulent, from anaerobes, 627-632
  - rheumatoid. *See Rheumatoid arthritis*
  - of sarcoidosis, 126-135
  - and synovial membrane permeability to serum proteins, 308
  - traumatic, synovial collagenase in, 95
- Arthrogryposis, spontaneous carpal fusion in, 345-353
- Arthropathy
- amyloid, 444-453
  - dysproteinemic, and RA, 555-565
  - neuropathic, and CRST syndrome, 636-638
- Arthroplasty of hip, total replacement, 690-691
- Arthroscopy, after synovectomy of knee, 322
- Articular cartilage. *See Cartilage*
- Arvin, affecting wound healing and collagen formation, 669
- Ascorbic acid, preventing ochronosis, 678-679
- Aspirin. *See Salicylates*
- Atlantoaxial joints, rheumatoid arthritis of, 329
- Atrioventricular block in ankylosing spondylitis, 665
- Autoantibodies
- in burned patients, 691
  - in NZB mice, 355-363
- Autoradiography of protein polysaccharides in articular cartilage, 694
- Azabarine, inhibiting adjuvant arthritis, 704
- Azathioprine
- affecting immunoglobulin synthesis, 675
  - in lupus erythematosus, 337-338
- Back pain, low, soft tissue contrast radiography in, 289
- Bacteria
- affecting PMN motility, 183-184
  - anaerobic, joint infections from, 627-632
- Bacterial arthritis
- assessment of therapy in, 529-532
  - synovial collagenase in, 94
- Barium metabolism in RA, 684
- Basement membranes
- chemistry and structure of, 427-441
  - glomerular
    - antibodies to, 672
    - cellular hypersensitivity to, in glomerulonephritis, 326
- Bed rest, value of, in RA, 690
- Bedsonia
- arthritis from
  - antibiotic therapy in, 297
  - scintiphotography and external counting in, 220-227
  - and Reiter's syndrome, 292
  - animal studies of agent from patient, 320
  - laboratory findings in, 329
- Behavior
- in hyperuricemia, 299
  - in juvenile RA, 286-287
- Biopsies, kidney, in lupus erythematosus, 541-542
- Bladder dysfunction in RA of cervical spine, 343
- Blood in joints, unexplained, 287
- Blood loss, occult, aspirin-induced, 311
- BLR-743, evaluation of, 328
- Bone changes, subchondral, in degenerative joint disease, 692
- Bone marrow, cells from, in adjuvant arthritis, 215-218
- Book reviews
- Aids and Adaptations (Canadian Arthritis and Rheumatism Foundation)*, 536
  - Early Synovectomy in Rheumatoid Arthritis*

- Book reviews (continued)  
*(Hijmans, ed.),* 526
- Introduction to Medical Decision Making  
*(Lusted),* 535
- La Main Rheumatoide (*Tubiana, ed.*), 650
- Meditations on Gout (*Ellwanger*), 535
- Population Studies of the Rheumatic Diseases  
*(Bennett & Wood, eds.)*, 650-651
- Boyden chamber for studies of PMN motility, 181-203
- Bradykinin generation, rheumatoid factors affecting, 292
- Burns, immunologic changes in, 691
- Cadmium metabolism in RA, 684
- Caffeine, affecting PMN motility, 181-187
- Calcification, synovial, in cirrhosis with hypertrophic osteoarthropathy, 261-271
- Calcinosis in CRST syndrome with neuropathic arthropathy, 636-638
- Calcitonin in osteoporosis and Paget's disease, 277
- Cancer and paraproteinemias after onset of RA, 279-280
- Carbohydrates in collagen from basement membranes, 435
- Carpal fusion, spontaneous, in arthrogryposis, 345-353
- Carpal tunnel syndrome  
 and amyloidosis, 560  
 in rheumatoid arthritis, 681
- Cartilage, articular  
 biology of, 152-155  
 collagen in, 21-28  
 components activating Hageman factor, 683  
 degeneration with subchondral bone changes, 692  
 junction with pannus in RA, electron microscopy of, 674  
 metabolism in osteoarthritic and normal hips, 315  
 micropuncture studies of fluid, 303  
 microradiography of calcified layer, 666  
 protein polysaccharides of, 658-659, 694  
 regeneration in large osteocartilaginous defects, 661  
 sulfate incorporation by chondrocytes in monolayer culture, 699  
 thickness and compressive stress in animals, 697-698
- Cell-mediated transfer of experimental diseases, 322-323
- Cellular hypersensitivity to glomerular basement membrane in glomerulonephritis, 326
- Cerebral amyloid, significance of, 343
- Cervical spine, rheumatoid arthritis of  
 anterior occipitocervical fusion in, 423-426
- bladder dysfunction in, 343
- Cesium metabolism in RA, 684
- Chemotaxis  
 after intraarticular injection of urate crystals, 324  
 and motility of PMN's, 183, 193, 197-203
- Chlorambucil with prednisone, affecting laboratory values in SLE, 292-293
- Chloroquine, retinopathy from, 315
- Chondrocalcinosis, articular  
 primary. See Pseudogout  
 secondary to gout, and chronic renal failure, 276
- Chondrocytes  
 metabolism of, 152  
 sulfate incorporation by, in monolayer culture, 699
- Chondroitin sulfate in osteoarthritic cartilage, 156
- Chondromalacia of patella, 155
- Chromium metabolism in RA, 684
- Chrysotherapy  
 serum gold levels in, 312-313, 677-678  
 and trace metal metabolism in RA, 684
- Cirrhosis, alcoholic, with hypertrophic osteoarthropathy, 261-271
- Clinics, mobile, experiences with, 289-290
- Coagulation, intravascular, and pathogenesis of SLE, 318-319
- Colchicine  
 affecting attack rate in primary nontophaceous gout, 663  
 affecting PMN motility after urate, 189-195  
 in inflammations from urate crystals, 290  
 interaction with tropocollagen, 684  
 in leukocytes, 293
- Cold-reactive rheumatoid factors in infectious mononucleosis, 67-73
- Collagen  
 in articular and costal cartilage, 21-28  
 Arvin affecting formation of, 669  
 of basement membranes, chemistry of, 427-441  
 diseases of  
     hyperviscosity of serum in, 653  
     myxovirus-like structures in, 300  
 drugs interacting with tropocollagen, 684  
 in Ehlers-Danlos syndrome, 289-290  
 immunogenicity of polypeptide chains, 676  
 in synovial fluid, identification of, 580-587  
 turnover of tendon grafts, immune response affecting, 676
- Collagenase, synovial, in joint disease, 92-101, 159
- Complement  
 binding by red cells in RA, 498-503  
 fixation antibodies and response to herpes simplex virus in RA, 698  
 fixation by immune complexes, effects of, 681

- Complement (continued)  
fixation by rheumatoid factors, 178-179, 289,  
701  
monospecific antisera to C'1s, 335-336  
in nephritis of mice, 310  
polymorphism of fourth component, 327-328  
precipitin reaction of component with gamma  
globulin complexes in SLE, 654  
in scleroderma in childhood, 301-302  
in synovial fluid, in RA, 283, 328-329, 343
- Connective tissue  
cellular interaction with leukocytes, 365-385  
diseases of  
in childhood, renal histology in, 329-330  
detection of gamma globulin complexes in,  
654  
and lymphocyte transformation in IgA defi-  
ciency, 659  
invertebrate, 305-306  
Contraceptives, oral, and occurrence of antinu-  
clear antibodies and LE cells, 306, 313-314
- Copper  
metabolism in RA, 684  
nonceruloplasmin, in RA, 458-460
- Correspondence, 64, 458-460, 538-545, 646-648
- Corticosteroids  
in giant cell arteritis, 149  
hydrocortisone affecting synovial phagocytosis of  
ferritin, 285  
myopathy from, 323, 491-497  
regional perfusion of, 662  
vasculitis from, 327  
in Wegener's granulomatosis, 252
- Costal cartilage, collagen in, 21-28
- Cryoglobulin  
structural changes at decreased temperature, 661  
in synovial fluid, 288
- Cryoglobulinemia  
mixed, 67-73  
and single strand DNA in serum, 282
- Cryoproteins in NZB mice, 335
- Crystal-induced inflammation  
from dialysis in renal failure, 317-318  
See also Urate crystals
- Cyclophosphamide  
affecting allergic encephalomyelitis in rats, 683  
compared with 6-MP, 674  
in rheumatoid arthritis, 276, 538, 663, 680
- Cysts  
of knee, synovial, atypical syndromes with, 302  
popliteal, scanning for, 311
- Cytoplasmic antibody in SLE sera, 173-179
- Cytoplasmic tubular structures in kidney biopsies  
in SLE, 541-542
- Day care rehabilitation center, 280
- Degenerative joint disease  
subchondral bone changes in, 692  
synovial collagenase in, 94  
and synovial uptake of ferritin, 285  
and synthesis of IgG by synovium, 333  
See also Osteoarthritis
- Delayed hypersensitivity  
in burns, 691  
and macrophage migration inhibitory factor, 278  
in rheumatic diseases, 677  
in vitro assay for, 327
- Depo-Medrol, intraarticular, in RA, 321
- Dermatomyositis  
in childhood, prognosis of, 336-337  
endothelial inclusions in, 320
- Diabetes and osteoarthritis, 160
- Dialysis in renal failure, and crystal-induced in-  
flammation, 317-318
- Diffusing capacity in scleroderma, seasonal varia-  
tions in, 672
- DNA  
antibodies to  
in IgG subgroups, 695  
in lupus erythematosus, 660-661  
in sera of RA patients, 705  
single strand, in cryoglobulinemia, 282  
synthesis by leukocytes, in inflammatory disease,  
303
- EB virus in infectious mononucleosis, 72
- Effusions, joint, bloody, unexplained, 287
- Ehlers-Danlos syndrome, clinical manifestations of,  
289-290
- Electron microscopy  
of cartilage-pannus junction in RA, 674  
in pigmented villonodular synovitis, 205-213  
scanning in rheumatoid synovitis, 692  
of synovial ferritin uptake in degenerative ar-  
thropathy, 285  
of synovial microvasculature, 387-402  
of synovium infected with *Mycoplasma*, 308  
of synovium regeneration after synovectomy, 316
- Electrophoretic pattern of serum in RA, 685-686
- Emulsions affecting arthritogenicity of bacilli and  
wax D, 687
- Encephalomyelitis, experimental allergic  
cell-mediated transfer of, 322  
lymphadenectomy affecting, 683  
passive transfer of, 703-704  
selective suppression of, 319
- Endocrinics  
disorders of, rheumatic syndromes with, 281  
factors in osteoarthritis, 160-161
- Endothelial inclusions  
in dermatomyositis, 320  
in lupus erythematosus, 320

- Endotoxins, amyloidosis from, 615-624  
 Erratum, xiii, 546  
**Erysipelothrix insidiosa**, experimental arthritis from, 589-595  
**Erythema nodosum**, joint involvement in, 128  
**Erythrocytes**  
 autoantibodies in NZB mice, 355-363  
 common antigens with leukocyte lysosomes, 310-311  
 complement binding by, in RA, 498-503  
 5-phosphoribosyl-1-pyrophosphate formation in gout, 666  
**Estrogen**, serum protein response to, in NZB/NZW mice, 702  
**Exercise programs** studied with model system, 322-323  
**Experimental diseases**  
 allergic encephalomyelitis. *See* Encephalomyelitis  
 amyloid, murine, 615-624  
 arthritis  
     antigen responsible for, 339  
     Azarbine affecting, 704  
     from bedsonia agents, 220-227, 297  
     bioassay of drugs in, 472-481  
     cell-mediated transfer of, 322  
     from *Erysipelothrix insidiosa*, 589-595  
     immunological studies of, 589-595  
     from lysosomal materials, 103-114  
     marrow-derived cells in, 215-218  
     Mycobacterial, 215-218, 687, 703-704  
     *Mycoplasma*, 277, 308, 340-341  
     pyran affecting, 463-469  
     regional perfusion of drugs in, 662  
     selective suppression of, 319  
     from urate crystals. *See* Urate crystals  
     from wax D, 687, 700  
 cell-mediated transfer of, 322  
 corticosteroid myopathy, 323, 491-497  
 passive transfer of, 703-704  
 polymyositis, 317  
 scurvy, arthritis in, 670  
 selective suppression of, 319
- Fab** papain agglutinators, affecting immune hemolysis, 340  
**Familial juvenile RA and pulmonary fibrosis**, 293  
**Family studies** in lupus erythematosus, 10-16  
**Fc fragments**  
 interaction with anti-Fc, IgG affecting, 677  
 interaction with immunoglobulin G, 682  
**Femoral head**, osteoarthritis of, radioactive sodium elimination in, 30-32  
**Ferritin uptake** by synovial membrane, in degenerative arthropathy, 285  
**Fibrinogen degradation products** in serum, in SLE, 318-319  
**Fibrinolytic agents**, affecting wound healing and collagen formation, 669  
**Fibroblasts**  
 cultured, allopurinol affecting, 306-307  
 hyaluronate production by, leukocytes affecting, 365-372  
 interaction with leukocytes, 365-385  
 response to "activator," 659-660  
**Fibrosis, pulmonary**  
 and familial juvenile RA, 293  
 with polymyositis, 321  
**Filipinos**, uric acid excretion defect in, 668  
**Finger joints**, artificial, 669  
*See also* Hand  
**Flufenamic acid** in adjuvant arthritis, 472-481  
**Folic acid levels** in RA, aspirin affecting, 654-655  
**Force transmission** through whole joints, 325  
**Fucose** in invertebrate connective tissue, 305-306  
**Gamma globulin**  
 precipitin reaction of complement component with, in SLE, 654  
 as therapy in RA, 515-519  
*See also* Immunoglobulins  
**Genetics**  
 familial juvenile RA and pulmonary fibrosis, 293  
 family studies in SLE, 10-16  
 Klinefelter's syndrome and lupus erythematosus, 240-245  
 of osteoarthritis, 159-160  
 rickets, hereditary, 281  
 and variability of fourth component of complement, 327-328  
**Glomerular basement membrane**  
 antibodies to, 672  
 cellular hypersensitivity to, in glomerulonephritis, 326  
**Glomerulitis** in childhood connective tissue diseases, 329-330  
**Glomerulonephritis**  
 and cellular hypersensitivity to glomerular basement membrane, 326  
 in NZB mice, 355-363  
*See also* Nephritis  
**Glucose oxidase tape test** in alkaptonuria, artifacts in, 673  
**Gold**  
 serum levels in chrysotherapy, 312-313, 677-678  
 therapy in RA, trace metal metabolism in, 684  
**Gout**  
 articular chondrocalcinosis secondary to, 276  
 delayed hypersensitivity in, 677  
 erythrocyte PRPP in, 666  
 liver xanthine ovidase in, 17-19

- Gout (continued)**  
 primary nontophaceous, uricosuric drugs affecting attack rate in, 663  
 and pyrophosphate phosphohydrolase in synovial fluid, 298  
*See also Pseudogout*
- Grafts**  
 renal, musculoskeletal disorders after, 333-334  
 tendon, immune response affecting collagen turnover of, 676
- Granule contents from lysosomes, arthritis from, 103-114**
- Granulocyte-specific antinuclear antibodies, 165-171**
- Granuloma, lethal midline, and Wegener's granulomatosis, 247-252**
- Granulomatosis, Wegener's and lethal midline granuloma, 247-252**
- Hageman factor activation, by components of cartilage, 683
- Hands**  
 artificial finger joints, 669  
 circadian pattern of finger joint circumference in RA, 294  
 metacarpal osteoarthritis, 405-410  
 pathology of proximal interphalangeal joints in RA, 704  
 resorption of terminal phalanges in scleroderma, 51-63  
 serial x-rays in RA, 312, 672-673, 696  
 ulnar phalangeal drift and rheumatoid wrist deformity, 331  
*See also Wrist*
- Hapten-specific anamnestic antibody responses, 686-687**
- Hartung, Edward F., 272-274
- Heat aggregation of immunoglobulin G, 655-656
- Heberden's nodes, 155
- Hemangioma, synovial, of knee, 647-648
- Hemarthrosis after knee arthroplasty, 520-528
- Hemolysis, immune, affected by Fab papain agglutinators, 340
- Hemorrhage in joints, spontaneous, 287
- Hereditary conditions. See Genetics**
- Herpes simplex virus, immunological response to, in RA, 698
- Hexose-induced hyperuricemia and uricosuria, 332
- Hip**  
 osteoarthritis of  
   articular cartilage metabolism in, 315  
   radioactive sodium elimination in, 30-32  
   prosthesis in arthritis, total, 313, 318  
   total replacement arthroplasties of, 690-691
- Histidine  
 levels in hydralazine-induced arthritis, 295-296
- therapy in rheumatoid arthritis, 295, 664  
 tolerance test in RA, 296
- Histones, neutral lysosomal proteases affecting, 703**
- Homogenetic acid**  
 turnover rate in alkaptonuria, 678-679  
 in urine, affecting tests for alkaptonuria, 673
- Hormones**  
 disorders of, rheumatic syndromes with, 281  
 factors in osteoarthritis, 160-161
- Hyaluronate**  
 production by fibroblasts, leukocytes affecting, 365-372  
 production by rheumatoid cells, 659-660
- Hyaluronidase in synovial fluid, 158**
- Hydralazine**  
 antibodies to nucleoproteins after, 275  
 arthritis from, histidine levels in, 295-296
- Hydrocortisone**  
 affecting synovial phagocytosis of ferritin, 285  
 regional perfusion of, 662
- Hydroxyproline excretion in scleroderma, 693**
- Hypersensitivity**  
 cellular, to glomerular basement membrane, in glomerulonephritis, 326  
*See also Delayed hypersensitivity*
- Hypertrophic osteoarthropathy with cirrhosis, 261-271**
- Hyperuricemia. See Uric acid**
- Hypospray for temporomandibular joint injection, 315-316**
- ICI 47, 776, affecting allergic encephalomyelitis in rats, 683**
- Immobilization of joints in RA, beneficial effect of, 34-43**
- Immune complexes, soluble**  
 complement fixation by, effects of, 681  
 in nephritis, 675
- Immune hemolysis, Fab papain agglutinators affecting, 340**
- Immune response. See Antibodies**
- Immunization, affecting lymph node cells, 688**
- Immunoassay**  
 of rheumatoid factor, 483-489  
 of serum proteins, automated system for, 693
- Immunogenicity of collagen polypeptide chains, 676**
- Immunoglobulin A**  
 deficiency in connective tissue disease, and lymphocyte transformation, 659  
 in external secretions, 45-49
- Immunoglobulin D antibodies, 672**
- Immunoglobulin G**  
 antibody to, lymphocyte transformation by, 597-605

- Immunoglobulin G (continued)**
- autologous, responses to in RA, 74-80, 694
  - azathioprine affecting synthesis of, 675
  - complexes in SLE sera, 658
  - egress from rabbit knee joints, 679-680
  - heat aggregation of, 655-656
  - human quantitation of, 677
  - and hyperviscosity with collagen diseases, 653
  - interaction with Fc fragments, 682
  - interaction with rheumatoid factors, 684-685
  - intraperitoneal, affecting rosette-forming cells, 1-8
  - nuclear fixation of, in renal cells in SLE, 668-669
  - proportion to IgM, affecting sheep cell agglutination test, 660
  - proteolysis at neutral pH, 678
  - reactions with  $\gamma M$  globulins, 483-489
  - related to complement in joint fluids in RA, 343
  - removal from knee joints in RA, 504-513
  - subclasses of antinuclear antibodies, 295, 671, 695
  - subgroup distribution in nephritis, 331
  - synthesis by rheumatoid synovium, 333
- Immunoglobulin M**
- anti- $\gamma$  globulin degradation by pepsin, 330-331
  - azathioprine affecting synthesis of, 675
  - degradation by pepsin, 695
  - phylogenetic relationships of antibodies, 654
  - proportion to IgG, affecting sheep cell agglutination test, 660
  - proteolysis at neutral pH, 678
  - serum levels of 7S  $\gamma M$  rheumatoid factor, 699
  - See also* Rheumatoid factor
- Immunoglobulins**
- affecting bradykinin generation, 292
  - antibodies in serum 254-258
  - complexes in RA and other diseases, 286
  - lymphocyte transformation from, in RA patients, 291
  - production after onset of RA, 279-280
  - in scleroderma in childhood, 301-302
  - secretory, 45-49
  - synthesis by lymphocytes, PHA affecting, 698-699
  - synthesis by salivary gland lymphoid cells, in Sjögren's syndrome, 338
- Immunologic responses to *Mycoplasma* arthritidis, 340-341**
- Inclusions**
- endothelial
    - in dermatomyositis, 320
    - in lupus erythematosus, 320
  - leukocyte, 304
- Indoles, new preparation of, 328**
- Indomethacin**
- affecting PMN motility after urate, 189-195**
- regional perfusion of, 662**
- Inflammations**
- crystal-induced, in dialysis for renal failure, 317-318
  - DNA synthesis by leukocytes in, 303
  - from urate crystals, colchicine in, 290
- Interferon** in adjuvant disease, pyran affecting, 463-469
- Interstitial fluid of growth cartilage, micropuncture studies of, 303**
- Intraarticular injections**
- in rheumatoid arthritis, 321
  - of urate crystals, chemotactic activity after, 324
- Invertebrate connective tissue, 305-306**
- Iron-dextran, intravenous, in RA, 454-456**
- Iron metabolism in RA, 684**
- Isoniazide in tuberculosis, antibodies to nucleoproteins after, 275**
- Jaundice in juvenile RA, antirheumatic effects of, 307**
- Jejunocolonic bypass in obese patients, polyarthritis after, 696**
- Joints**
- apoplexy, idiopathic, 287, 646
  - scanning of, 299
  - whole, force transmission through, 325
- Kashin-Beck disease, 160**
- Kidney**
- abnormal function in asymptomatic hyperuricemia, 307
  - acidification in Sjögren's syndrome, 538-541
  - biopsies in SLE, 541-542
  - chronic failure with articular chondrocalcinosis secondary to gout, 276
  - dialysis of, and crystal-induced inflammation, 317-318
  - gamma G globulin subgroups in nephritis, 331
  - histology in childhood connective tissue diseases, 329-330
  - nuclear fixation of IgG to renal cells in SLE, 668-669
  - transplants of, musculoskeletal disorders after, 333-334
- Kinin generation**
- induced by components of cartilage, 683
  - rheumatoid factors affecting, 292
- Klinefelter's syndrome and lupus erythematosus, 240-245**
- Knee**
- arthroscopy after synovectomy, 322
  - chondromalacia of patella, 155
  - egress of IgG from, 679-680
  - fixed flexion deformities in RA, 287

- Knee (continued)**
- osteoarthritis of, angular deformity affecting pain in, 279
  - prosthetic arthroplasty of, hemarthrosis after, 520-528
  - protein removal from, in RA, 504-513
  - scanning for popliteal cysts, 311
  - synovial cysts of, atypical syndromes with, 302
  - synovial fluid changes after synovectomy, 288
  - synovial hemangioma of, 647-648
  - Walldius' prosthesis for, 705
- LE cells after oral contraceptive use, 306,313-314**
- Lead metabolism in RA, 694**
- Leukocytes**
- colchicine in, 293
  - DNA synthesis by, in inflammatory disease, 303
  - exudative, in urate crystal-induced inflammation, 657-658
  - formation of inclusions in, 304
  - interaction with connective tissue cells, 365-385
  - lysosomes from, common antigens with red cells, 310-311
  - polymorphonuclear
    - affecting hyaluronate production by fibroblasts, 365-372
    - lysosomal and cell membranes of, 298-299
    - motility of, 181-203
  - Lipids, exogenous hyperlipemia in SLE and lymphoma, 297
  - Liver xanthine oxidase in gouty patients, 17-19
  - Lungs**
    - diffusing capacity in scleroderma, seasonal variations in, 672
    - fibrosis of
      - and familial juvenile RA, 293
      - with polymyositis, 321
    - interstitial disease in RA, 297-298
    - nodular rheumatoid lung disease, 340  - Lupus erythematosus, systemic**
    - and antibodies to double-stranded RNA, 695-696
    - anti-DNA antibodies in, 660-661
    - antribosomal antibodies in, 310
    - aortic insufficiency in, 138-145
    - azathioprine in, 337-338
    - cytoplasmic and nucleolar antibody in, 173-179
    - delayed hypersensitivity in, 677
    - detection of gamma globulin complexes in, 654
    - drug therapy affecting laboratory values in, 292-293
    - endothelial inclusions in, 320
    - exogenous hyperlipemia in, 297
    - and fibrinogen degradation products in serum, 318-319
    - and IgG complexes in sera, 658
    - and IgG subclasses of antinuclear antibodies, 671
    - in vivo LE cells, 64
    - kidney biopsies in, 541-542
    - and Klinefelter's syndrome, 240-245
    - nuclear fixation of IgG to renal cells in, 668-669
    - prenatal factors in, 10-16
    - from procainamide, 608-613
    - scleroderma with, 662
    - survival time related to race and pregnancy, 117-125
    - synovial fluid in, 688
    - virus studies in, 688-689  - Lupus-like syndrome from procainamide, 281-282**
  - Lupus nephritis, 693-694**
    - anticellular antibodies in, 280
    - gamma G globulin subgroups in, 331  - Lymph node cells, immunization affecting, 688**
  - Lymphadenectomy, affecting allergic encephalomyelitis in rats, 683**
  - Lymphocytes**
    - affecting hyaluronate production by fibroblasts, 365-372
    - immunoglobulin synthesis by, PHA affecting, 698-699
    - mixed culture of, altered reactivity in RA, 547-554
    - reactivity impaired in RA, 276-277
    - thoracic duct, and passive transfer of experimental diseases, 703-704
    - transformation of
      - by anti- $\gamma$  globulin factors, 597-605
      - in IgA deficiency in connective tissue diseases, 659
      - and response to herpes simplex virus in RA, 698
      - in rheumatic diseases, 667
      - after serum fractions from RA patients, 291
    - Lymphocytopenia in chronic RA, 685**
    - Lymphoid cells of salivary glands, immunoglobulin synthesis by, in Sjögren's syndrome, 338**
    - Lymphoma**
      - exogenous hyperlipemia in, 297
      - and rheumatoid arthritis, 569-577    - Lysosomal proteases, neutral, affecting protein polysaccharides, 703**
    - Lysosomes**
      - arthritis from granule contents of, 103-114
      - leukocyte, common antigens with red cells, 310-311
      - pregnancy serum affecting, 302
      - structural protein of membranes, 298-299    - Lysozyme levels in RA, 691**
    - Macroglobulin**
      - serum and synovial fluid  $\alpha_2$ M in RA, 309
      - Waldenström, ligand binding in, 655    - Macroglobulinemia, Waldenström, and RA, 555-577**

- M<sup>+</sup>rophages, migration inhibitory factor in, 278  
 Ma<sub>+</sub>nease metabolism in RA, 684  
 Marrow, cells from, in adjuvant arthritis, 215-218  
 Mefenamic acid in adjuvant arthritis, 472-481  
 6-Mercaptopurine compared with cyclophosphamide, 674  
 Metacarpal osteoarthritis, hook-like osteophytes in, 405-410
- Metals  
 particles in synovial fluid, from prostheses, 520-528  
 trace element levels in RA, 684
- Micropuncture studies of interstitial fluid of growth cartilage, 303
- Microradiography of calcified layer of articular cartilage, 666
- Microvasculature of synovial membrane, 387-402
- Migration inhibitory factor, macrophage, 278
- Molybdenum metabolism in RA, 684
- Mononuclear cells in rabbit synovium, 338
- Mononucleosis, infectious, cold-reactive rheumatoid factors in, 67-73
- Motility of polymorphonuclear leukocytes, factors affecting, 181-203
- Muramidase levels in RA, 691
- Musculoskeletal disorders after renal transplants, 333-334
- Mycobacterium tuberculosis* arthritis  
 emulsions affecting arthritogenicity of bacilli, 687  
 marrow-derived cells in, 215-218  
 passive transfer of, 703-704
- Mycoplasma*  
*arthritidis*, immunologic responses to, 340-341  
*hyorhinis*  
 interaction with synovial membrane, 308  
 in swine, 277
- Myeloma, multiple, and RA, 555-577
- Myocardial infarction and RA, 305
- Myopathy from steroids, 323, 491-497
- Myositis. See Polymyositis
- Myxovirus-like structures in collagen diseases, 300
- Nafcillin transport into synovial fluid, 686
- Neoplasia and rheumatoid disease, 555-577
- Nephritis  
 and cellular hypersensitivity to glomerular basement membrane, 326  
 and complement levels in mice, 310  
*lupus*, 693-694  
 antinuclear antibodies in, 280  
 gamma G globulin subgroups in, 331  
 in NZB mice, 355-363  
 soluble immune complexes in, 675
- Neuropathic arthropathy and CRST syndrome, 636-638
- Niacinamide in RA, 339
- Nickel metabolism in RA, 684
- Nodules, pseudorheumatoid, in children, 285
- Nucleolar antibody in SLE sera, 173-179
- Nucleoproteins, antibodies to, after isoniazide, 275  
 See also DNA; RNA
- Nutritional factors in osteoarthritis, 160
- Obesity  
 and osteoarthritis, 160  
 polyarthrosis in, after jejunocolonic bypass, 696
- Occipitocervical fusion, anterior, in RA, 423-426
- Ochronosis, ascorbic acid preventing, 678-679
- Orotic acid, affecting purine synthesis, 673
- Osteoarthritis  
 biology of, 152-162  
 of hip  
 articular cartilage metabolism in, 315  
 radioactive sodium elimination in, 30-32  
 of knee, angular deformity affecting pain in, 279  
 metacarpal, hook-like osteophytes in, 405-410  
 protein removal from knee joints in, 504-513  
 and serotonin levels in blood, 336
- Osteoarthropathy, hypertrophic, with cirrhosis, 261-271
- Osteocartilaginous defects, large, 661
- Osteophytes, hook-like, in osteoarthritis of metacarpals, 405-410
- Osteoporosis, calcitonin in, 277
- Oxygen consumption of joints, in RA, 664-665
- Oxyphenbutazone  
 adverse reactions after long-term use, 334  
 reaction with thiols, 342
- Page's disease of bone, calcitonin in, 277
- Pain in osteoarthritis of knee, angular deformity affecting, 279
- Pannus junction with cartilage in RA, electron microscopy of, 674
- Papain Fab agglutinators, affecting immune hemolysis, 340
- Paraproteinemia and RA, 279-280, 555-565
- Parotid sialography, in Sjögren's syndrome, 314, 679
- Patella, chondromalacia of, 155
- Penicillin  
 in bedsonia arthritis, 297  
 transport into synovial fluid, 686
- Pepsin, degradation of IgM by, 330-331, 695
- Pepsin-site agglutinators, affecting phagocytosis, 682
- Perfusion, regional, in experimental arthritis, 662
- Personality in juvenile RA, 286-287
- pH  
 affecting PMN motility, 181-187  
 and proteolysis of immunoglobulins, 678

- Phagocytosis  
pepsin-site agglutinators affecting, 682  
of urate crystals by PMN's, 197-203
- Phagosomes  
fusion with lysosomes, 298-299  
in synovial cells, in RF-positive patients, 283
- Phalanges, terminal, resorption in scleroderma, 51-63
- Phenylbutazone  
in adjuvant arthritis, 472-481  
adverse reactions after long-term use, 334  
reaction with thiols, 342  
regional perfusion of, 662
- 5-Phosphoribosyl-1-pyrophosphate in erythrocytes  
in gout, 666
- Physicians  
in southern state, rheumatoid patients managed by, 341  
training program in rheumatic disease, 324
- Phytohemagglutinin and immunoglobulin synthesis  
by lymphocytes, 698-699
- Pigmented villonodular synovitis, 205-213
- Plaque-forming cells, reaction to IgG, 1-8
- Plasma cell neoplasms and RA, 555-577
- Plasminogen in synovial fluid, 159
- Platelet count in chronic RA, 685
- Polyinosinic-polycytidylc acid, affecting anti-RNA antibodies, 700
- Polymyalgia rheumatica and giant cell arteritis, 147-151
- Polymyositis  
experimental, 317  
incidence of, 316  
pulmonary fibrosis with, 321
- Polypeptide chain, collagen, immunogenicity of, 676
- Polysaccharides  
antibody responses to antigens in strains of mice, 300-301  
in cartilage, 156, 658-659  
and activation of Hageman factor, 683  
autoradiography of, 694  
protein, neutral lysosomal proteases affecting, 703
- Popliteal cysts  
atypical syndromes with, 302  
scanning for, 311
- Prednisone with chlorambucil, affecting laboratory values in SLE, 292-293
- Pregnancy  
sera from patients affecting lysosomes, 302  
and survival time in SLE, 117-125
- Prenatal factors in lupus erythematosus, 10-16
- Procainamide  
lupus-like syndrome from, 281-282
- serologic changes from, in asymptomatic patients, 608-613
- SLE from, and IgG subclasses of antinuclear antibodies, 671
- Procaine, intraarticular, in RA, 321
- Prostheses  
for finger joints, 669  
metal, for knee, hemarthrosis from, 520-528  
total  
of hip, 313, 318, 690-691  
Walldius' knee prosthesis, 705
- Protease, neutral lysosomal, affecting protein polysaccharides, 703
- Protein  
of amyloid fibrils, chemical differences in, 333  
antibody responses to antigens in strains of mice, 300-301  
automated system for immunoassay for, 693  
binding of penicillins to, affecting transport into synovial fluid, 686  
in cartilage, 21-28  
cryoproteins in NZB mice, 335  
paraproteinemia and RA, 279-280, 555-565  
plasma  
drugs affecting urate binding to, 657  
found in exclusion volume of anion exchange column, 325-326  
hypro-proteins in scleroderma, 693  
response to estrogen in NZB/NZW mice, 702  
synovial membrane permeability to, in arthritis, 308  
polysaccharide complexes in cartilage, 156, 658-659, 694  
removal from knee joints in RA, 504-513  
structural, of lysosomal membrane, 298-299  
in wax D, affecting adjuvant arthritis, 700
- Proteolysis of immunoglobulins at neutral pH, 678
- Pseudogout  
and pyrophosphate phosphohydrolase in synovial fluid, 298
- synovial collagenase in, 95, 96  
urinary pyrophosphate excretion in, 228-230
- Pseudorheumatoid nodules in children, 285
- Pseudo-vitamin D deficiency rickets, 281
- Pulmonary conditions. *See Lungs*
- Purine synthesis  
erythrocyte PRPP affecting, 666  
orotic acid affecting, 673
- Purpura, hypergammaglobulinemic, gamma globulin complexes in, 286
- Pyran, affecting adjuvant arthritis, 463-469
- Fyrophosphate, urinary excretion of, in pseudogout, 228-230
- Pyrophosphate phosphohydrolase in synovial fluid, in disorders, 298

- Racial factors and survival time in SLE, 117-125  
 Radioimmunoassay of rheumatoid factor, 483-489  
 Radiology  
     autoradiography of protein polysaccharides in articular cartilage, 694  
     in juvenile RA, 341  
     microradiography of calcified layer of articular cartilage, 666  
     of proximal interphalangeal joints in RA, 704  
     serial x-rays of hands and wrists in RA, 312, 672-673, 696  
     sialography in Sjögren's syndrome, 314, 679  
     soft tissue contrast, in low back pain, 289  
 Raynaud phenomenon  
     clinical-laboratory correlations in, 701-702  
     intraarterial reserpine in, 342  
     neuropathic arthropathy with CRST syndrome, 636-638  
     and scleroderma, 51-63  
 Regeneration in large osteocartilaginous defects, 661  
 Rehabilitation  
     complications affecting, 305  
     day care center for, 280  
 Reiter's syndrome  
     animal studies of bedsonia agent from patient, 320  
     antinuclear antibodies in, 344  
     bedsonia in, 292  
     and laboratory tests for bedsonia, 329  
     synovial collagenase in, 95  
 Reserpine, intraarterial, in Raynaud's disease, 342  
 Reticulum cell sarcoma, cold-reactive rheumatoid factors in, 72  
 Rheumatic diseases  
     delayed hypersensitivity in, 677  
     lymphocyte transformation in, 667  
     with thyroid disorders, 281  
     training program for physicians in, 324  
 Rheumatism, palindromic, synovial collagenase in, 94  
 Rheumatoid arthritis  
     in aged, 291  
     alpha-1-antitrypsin concentrations in, 337  
     altered reactivity in mixed lymphocyte cultures in, 547-554  
     and antibodies to DNA, 705  
     antinuclear antibodies in, 165-171, 344  
     arthritis in  
         involving large vessels, 319  
         and myocardial infarction, 305  
     aspirin affecting folate levels in, 654-655  
     of atlantoaxial joints, 329  
     bed rest in, 690  
     BLR-743 in, evaluation of, 328  
     carpal tunnel syndrome in, 681  
     of cervical spine  
         anterior occipitocervical fusion in, 423-426  
         bladder dysfunction in, 343  
     circadian pattern of finger joint circumference in, 294  
     and collagenase in synovium, 92-101, 159  
     complement binding by red cells in, 498-503  
     and complement in synovial fluid, 328-329  
     complications affecting rehabilitation in, 305  
     cyclophosphamide in, 276, 538, 663, 680  
     delayed hypersensitivity in, 677  
     disease activity related to articular damage in, 672  
     electron microscopy of cartilage-pannus junction in, 674  
     fixed flexion deformities of knee in, 287  
     follow-up of community study, 87-91  
     gamma globulin therapy in, 515-519  
     granulocyte-specific antinuclear antibodies in, 165-171  
     of hands. *See Hands*  
     of hip. *See Hip*  
     histidine therapy in, 295, 664  
     histidine tolerance test in, 296  
     and IgG subclasses of antinuclear antibodies, 671  
     immobilization of joints in, 34-43  
     immunoglobulin complexes in, 286  
     and immunological responses to herpes simplex virus, 698  
     interstitial pulmonary disease in, 297  
     intraarticular drugs in, 321  
     intravenous iron-dextran in, 454-456  
     joint fluid studies of  $\gamma$ G complexes and complements in, 343  
     juvenile  
         age of onset related to rheumatoid factor, 82-85  
         antinuclear antibody in, 323-324  
         characteristics and prognosis of, 278  
         familial, and pulmonary fibrosis, 293-294  
         jaundice in, antirheumatic effects of, 307  
         personality and behavior in, 286-287  
         renal histology in, 329-330  
         roentgenography in, 341  
         serologic survey of 200 patients, 656-657  
         synovectomy in, 312  
         synovial collagenase in, 95  
         temporomandibular joint in, 335  
     of knee. *See Knee*  
     lymphocyte reactivity in, 276-277  
     lymphocyte transformation from serum fractions in, 291  
     lymphocytopenia in, 685  
     lysozyme levels in, 691  
     maintenance of high serum salicylate levels in, 697

- Rheumatoid arthritis (continued)
- management of patients in southern state, 341
  - niacinamide therapy in, 339
  - nonceruloplasmin copper in, 458-460
  - oxygen consumption of joints in, 664-665
  - and paraproteinemia, 279-280, 555-565
  - pathology of proximal interphalangeal joints in, 704
  - pauciarticular, 330
  - protein removal from knee joints in, 504-513
  - and pyrophosphate phosphohydrolase in synovial fluid, 298
  - regeneration of synovium after synovectomy in, 316, 325
  - resection of distal ulna in, 415-422
  - and responses to autologous IgG, 694
  - results of synovectomy in, 317
  - rubella hemagglutination inhibition antibodies in, 671
  - scanning electron microscopy in, 692
  - serial x-rays of hands and wrists in, 312, 672-673, 696
  - and serotonin levels in blood, 336
  - serum electrophoretic pattern in, 685-686
  - serum gold levels in chrysotherapy, 312-313, 677-678
  - and serum and synovial fluid levels of  $\alpha_2$ M, 309
  - steroid vasculitis in, 327
  - and synovial fluid changes in knee after synovectomy, 288
  - and synthesis of IgG by synovium, 333
  - thrombocytopenia in, 685
  - trace metal metabolism in, 684
  - virus studies in, 689
  - of wrists. *See* Wrists
- Rheumatoid cells
- rubella virus affecting, 641-644, 665
  - of synovial membrane, compared with normal cells in culture, 639-644, 659-660
- Rheumatoid factor
- affecting antibody-producing cells, 1-9
  - affecting bradykinin generation, 292
  - and age of onset in juvenile RA, 82-85
  - catabolism and synovial transport of, 282
  - cold-reactive, in infectious mononucleosis, 67-73
  - and complement fixation, 178-179, 289, 701
  - hyperviscosity from, 304
  - interaction with immunoglobulin G, 684-685
  - molecular probe for biological activity of, 300
  - after oral contraceptives, 305, 313-314
  - positive test in apparently healthy subjects, 301
  - radioimmunoassay of, 483-489
  - reactivity with autologous IgG, 74-80
  - in sarcoidosis, 129-130
  - in scleroderma in childhood, 301-302
  - and serum levels of 7S  $\gamma$ M, 699
  - slide test for detection of, 665
  - and synovial fluid complement levels, 283
- Rheumatoid lung disease, nodular, 340
- Rheumatoid nodules, benign, in children, 285
- Ribosomes, antibodies to
- in IgG subgroups, 695
  - in lupus erythematosus, 310
- Rickets, pseudo-vitamin D deficiency, 281
- RNA, antibodies to
- in IgG subgroups, 695
  - in induction and suppression of, 700
  - in lupus erythematosus, 695-696
- Rosette-forming cells, intraperitoneal IgG affecting, 1-8
- Rubella
- vaccination for, acute arthritis from, 701
  - virus affecting rheumatoid cells, 641-644, 665
  - virus hemagglutination inhibition antibodies in RA, 671
- Rumalon in osteoarthritis, 161
- Sacroiliitis, bilateral, 285-286
- Salicylates
- affecting folate levels in RA, 654-655
  - aspirin-induced occult blood loss, 311
  - maintenance of high serum levels in RA, 697
- Salivary gland lymphoid cells, immunoglobulin synthesis by, in Sjögren's syndrome, 338
- Sarcoid, delayed hypersensitivity in, 677
- Sarcoidosis, arthritis of, 126-135
- Sarcoma, reticulum-cell, cold-reactive rheumatoid factors in, 72
- Scintiscanning
- in bedsonia arthritis in rabbits, 220-227
  - of joints, 299
  - for popliteal cysts, 311
  - in vasculitis, systemic, 294
- Sclerodactyly in CRST syndrome with neuropathic arthropathy, 636-638
- Scleroderma
- in children
  - immunoglobulins, RF and antinuclear antibodies in, 301-302
  - rheumatoid factor in, 85
  - hydroxyproline excretion in, 693
  - lupus erythematosus with, 662
  - neuropathic arthropathy with CRST syndrome, 636-638
  - plasma hydro-proteins in, 693
  - and pulmonary fibrosis, 321
  - resorption of terminal phalanges in, 51-63
  - seasonal variation in diffusing capacity in, 672
  - synovial collagenase in, 94
- Scurvy, experimental, arthritis in, 670
- Seasonal variations in diffusing capacity in scleroderma, 672

- Secretory immunoglobulins, 45-49  
 Septic arthritis  
     assessment of therapy in, 529-532  
     synovial collagenase in, 94  
 Serotonin levels in RA, 336  
 Sialography in Sjögren's syndrome, 314, 679  
 Sjögren's syndrome  
     early recognition of, 314  
     and immunoglobulin synthesis by salivary gland lymphoid cells, 338  
     in ophthalmic milieu, 667  
     renal acidification in, 538-541  
     sialography in, 314, 679  
 Sodium, radioactive, elimination in hip osteoarthritis, 30-32  
 Spine, cervical, rheumatoid arthritis of  
     anterior occipitocervical fusion in, 423-426  
     bladder dysfunction in, 343  
 Spleen, rosette-forming cells in, IgG affecting, 1-9  
 Splinting of joints in RA, beneficial effect of, 34-43  
 Spondylitis, ankylosing  
     atrioventricular block in, 665  
     and bilateral sacroiliitis, 285-286  
     juvenile, 309  
     peripheral arthritis in, 680-681  
 Statolon, affecting adjuvant arthritis, 464  
 Steroids. *See* Corticosteroids  
 Stromal cell reaction in pigmented villonodular synovitis, 205-213  
 Strontium metabolism in RA, 684  
 6-Sulfanilamidoindazole, periarthritis from, 702-703  
 Sulfate incorporation by articular chondrocytes in monolayer culture, 699  
 Sulfinpyrazone, affecting attack rate in primary nontophaceous gout, 663  
 Synovectomy  
     in juvenile RA, 312  
     of knee, arthroscopy after, 322  
     regeneration of synovium after, 316, 325  
     results in RA, 317  
     and synovial fluid changes in knee, 288  
 Synovial cells, normal and rheumatoid, 639-644, 659-660  
 Synovial fluid  
     alpha-2-macroglobulin levels in RA, 309  
     alpha-1-antitrypsin levels in RA, 337  
     changes in knee after synovectomy, 288  
     complement in  
         related to  $\gamma$ G globulin complexes in RA, 343  
         in rheumatoid arthritis, 328-329  
         and rheumatoid factor, 283  
     cryoglobulins in, 288  
     hyaluronidase in, 158  
     identification of collagen in, 580-587  
     in lupus erythematosus, 688  
     lysozyme levels in RA, 691  
     metal particles in, from prostheses, 530-538  
     new component in, 279  
     plasminogen in, 159  
     pyrophosphate phosphohydrolase in, in disorders, 298  
     serologic studies of, 332  
     transport of penicillins into, 686  
 Synovitis, pigmented villonodular, 205-213  
 Synovium  
     bedsonia isolated from membrane, animal studies of, 320  
     calcification in cirrhosis with hypertrophic osteoarthropathy, 261-271  
     collagenase in, in joint disease, 92-101, 159  
     cysts of knee, atypical syndromes with, 302  
     ferritin uptake by, in degenerative arthropathy, 285  
     hemangioma of knee, 647-648  
     interaction with *Mycoplasma*, 308  
     membrane permeability to serum proteins, in arthritis, 308  
     microvasculature of, 387-402  
     mononuclear cells of, in rabbit, 338  
     regeneration after synovectomy, 316, 325  
     rheumatoid  
         oxygen consumption in, 664-665  
         synthesis of IgG by, 333  
 Telangiectasia in CRST syndrome with neuropathic arthropathy, 636-638  
 Temperature  
     affecting PMN motility, 181-187  
     affecting tests for rheumatoid factor, 67-73  
     heat aggregation of immunoglobulin G, 655-656  
 Temporal arteritis and polymyalgia rheumatica, 147-151  
 Temporomandibular joint  
     injection with Hypospray, 315-316  
     in juvenile RA, 335  
 Tendon grafts, immune response affecting collagen turnover of, 676  
 Tetracycline in bedsonia arthritis, 297  
 6-Thioguanine, affecting allergic encephalomyelitis in rats, 683  
 Thiols, reaction with phenylbutazone and oxyphenbutazone, 342  
 Thio-TEPA, intraarticular, in RA, 321  
 Thoracic duct lymphocytes and passive transfer of experimental diseases, 703-704  
 Thrombocytopenia in chronic RA, 685  
 Thymocyte serum, rabbit anti-rat, suppressing experimental diseases, 319  
 Thyroid  
     antibodies to tissue, 672  
     disorders of, rheumatic syndromes of, 281

- Thyroiditis, experimental allergic  
cell-mediated transfer of, 322  
selective suppression of, 319
- Tibial nerve compression, posterior, 290
- Tin metabolism in RA, 684
- Training program for physicians in rheumatic diseases, 324
- Transplants  
renal, musculoskeletal disorders after, 333-334  
tendon graft, immune response affecting collagen turnover of, 676
- Trasylol, affecting arthritis from urate crystals, 334
- Traumatic arthritis, synovial collagenase in, 95
- Triamcinolone, myopathy from, 323 491-497
- Trypsin  
alpha-1-antitrypsin levels in RA, 337  
and kallikrein inhibitor, affecting arthritis from urate crystals, 334
- Tuberculosis  
isoniazide in, antibodies to nucleoproteins after, 275  
rabbit antituberculosis serum suppressing experimental diseases, 319
- Tubular structures in kidney biopsies in SLE, 541-542
- Ulna  
distal resection in RA, 415-422  
phalangeal drift, rheumatoid wrist in, 331
- Urate binding to plasma proteins, drugs affecting, 657
- Urate crystals  
affecting PMN motility, 189-195  
arthritis from, Trasylol affecting, 334  
inflammations from  
colchicine in, 290  
ultrathin study of exudative leukocytes in, 657-658
- intraarticular, chemotactic activity after, 324
- intracellular formation of, 283
- phagocytosis by PMN's, 197-203
- Uric acid  
behavioral variables in hyperuricemia, 299  
excretion defect on Filipinos, 668  
hexose-induced hyperuricemia and uricosuria, 332  
levels in arthritis of sarcoidosis, 128  
metabolism in *Cebus* monkeys, 697  
renal function in asymptomatic hyperuricemia, 307
- Uricosuria, hexose-induced, 332
- Uricosuric drugs, affecting attack rate in primary nontophaceous gout, 663
- Vaccination for rubella, acute arthritis from, 701
- Vasculitis. *See Arteritis*
- Villonodular synovitis, pigmented, 205-213
- Vinblastine interaction with tropocollagen, 684
- Viper venom, affecting wound healing and collagen formation, 669
- Viruses  
affecting immune response, 670  
immunological response to herpes simplex virus in RA, 698  
in lupus erythematosus, 688-689  
myxovirus-like structures in collagen diseases, 300  
in rheumatoid arthritis, 689  
studies of rheumatoid synovial cells in culture, 641-644, 665
- Viscosity of serum, increased and collagen diseases, 653  
from rheumatoid factor, 304
- Vision loss in giant cell arteritis, 147-151
- Vitamin D in pseudo-vitamin D deficiency rickets, 281
- Waldenström macroglobulin, ligand binding in, 655
- Waldenström macroglobulinemia and RA, 555-577
- Waldius' knee prosthesis, 705
- Wax D  
arthritogenicity of, emulsions affecting, 687  
protein in, affecting adjuvant arthritis, 700
- Wegener's granulomatosis and lethal midline granuloma, 247-252
- Wound healing, Arvin affecting, 669
- Wrists  
distal ulna resection in RA, 415-422  
rheumatoid deformity in ulnar phalangeal drift, 331  
serial x-rays of, in RA, 312, 672-673, 696  
spontaneous carpal fusion in arthrogryposis, 345-353
- Xanthine oxidase of liver, in gouty patients, 17-19
- Zinc metabolism in RA, 684